S. Carter, M. Friedman
Feb 1, 1972
Citations
0
Influential Citations
110
Citations
Quality indicators
Journal
European journal of cancer
Abstract
Abstract 5 -( 3,3 -dimethyl- 1 -triazeno)-imidazole- 4 -carboxamide (DTIC, DIC, NSC- 45388 ) is a new synthetic chemical antitumor agent developed by the Chemotherapy Program of the National Cancer Institute. It was chosen for clinical trial because of activity against mouse leukemia L 1210 . Its mechanism of action is not definitely established but it has been postulated to be both a deranger of de novo purine synthesis and an alkylating agent. Clinical trials have shown the drug to be significantly active against malignant melanoma with an overall response rate of 20·6% ( 88 426 ). This response rate is remarkable for its consistency among various clinical trials. Marginal antitumor activity has been seen against other solid tumors and slightly better activity against sarcomatous disease. Toxicity is mainly to bone marrow and gastrointestinal tract and is reversible in almost all cases.